Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,460 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Effects Clear all

Conditions: Obesity, Pre Diabetes
Interventions: HealthSnap, dietary counseling; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity
Interventions: Alternate Day Intermittent Energy Restriction, Reduced Calorie Diet; Other
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Lubbock, Texas

Conditions: Gout, Hyperuricemia
Interventions: Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ulcerative Colitis
Interventions: KB295; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • Austin, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Buena Park, California • Fresno, California • San Jose, California + 11 more

Conditions: Subarachnoid Hemorrhage, Vasospasm
Interventions: Red blood cell transfusion; Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity
Interventions: Exercise; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2034
U.S. locations: 15
States / cities: Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 10 more

Conditions: Metabolic Syndrome, Insulin Resistance
Interventions: TA-65, Placebo; Dietary Supplement
Lead sponsor: University of Connecticut; Other
Eligibility: 35 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Sleep, Insomnia, Insulin Resistance
Interventions: Eszopiclone, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 35 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Spinal Cord Injury, Cardiovascular Diseases, Obesity
Interventions: Spinal Cord Injury (SCI), Caregiver Intervention(CCC), Caregiver Control (CC); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Englewood, Colorado • Miami, Florida

Conditions: Fabry Disease
Interventions: PRX-102 1 mg/kg every two weeks; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 6
States / cities: Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more

Conditions: Type 2 Diabetes, Chronic Kidney Disease
Interventions: Dulaglutide, Insulin glargine, Insulin lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 47
States / cities: Montgomery, Alabama • Azusa, California • Granada Hills, California + 39 more

Conditions: Burn Injury
Interventions: coenzyme Q10, Placebo; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Infusion; Other
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Dyslipidemia
Interventions: Atorvastatin, ABT335, ER Niacin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss; Behavioral
Lead sponsor: Coastal Carolina University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Conway, South Carolina

Conditions: Obesity, Diabetes, Peripheral Vascular Disease
Interventions: Prevena vac; Device
Lead sponsor: Dr. Jean E. Starr, MD; Other
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hot Weather; Adverse Effect, Kidney Dysfunction, Kidney Injury, Hyperthermia, Dehydration
Interventions: Fluid replacement, No fluid replacement; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 44 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Type 2 Diabetes
Interventions: protein supplement; Dietary Supplement
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type I
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 8 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Stanford, California • Aurora, Colorado • New Haven, Connecticut + 3 more

Conditions: Obesity, Overweight
Interventions: AC2307, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Chandler, Arizona • Santa Rosa, California + 15 more

Conditions: Efavirenz, Metabolism and Pharmacokinetics Changes
Interventions: Efavirenz, voriconazole; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Polyphenolic Compounds and Metabolism
Interventions: Active Capsule, Placebo Capsule; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Healthsnap on Epicardial Adipose Tissue Study

Effect of a 4-week Alternate Day Intermittent Energy Restriction Intervention vs Reduced

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function

SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage

Effect of Exercise on Metabolic Health

Pompe Pregnancy Sub-Registry

The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

Treatment of Insomnia and Glucose Metabolism

A Lifestyle Intervention Targeting Enhanced Health and Function for Persons With Chronic SCI in Caregiver/Care-Receiver Relationships: Effects of Caregiver Co-Treatment

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Assessing Bioavailability of CoQ10 Supplementation in Burn Patients

The Effects of Gastric or Duodenal Nutrient Infusion on Food Intake, Obesity and Comorbidities in Obese Individuals

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

The Effects of Continuous vs. Intermittent Caloric Restriction on Fat Los

Effects of Prevena Therapy on Obese and or Diabetic Patients With Surgical Groin Sites

Renal Considerations in the Heat Stress Recommendations (Aim2)

Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics

Effect of the Fat Content of the Bedtime Snack on Overnight Hypoglycemia

Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects

Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers

Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers.